Literature DB >> 24466404

The p53-MDM2/MDMX axis - A chemotype perspective.

Kareem Khoury1, Grzegorz M Popowicz2, Tad A Holak2, Alexander Dömling1.   

Abstract

The protein-protein interaction (PPI) of the tumor suppressor p53 and its negative regulator MDM2 consists of the most intense studied PPI with a group of small molecular weight antagonists described and many more disclosed in patent literature. Due to the Å-level structural insight into p53 interaction with MDM2 there is a reasonable understanding of the requirements of the molecules to bind. In contrast and despite the very close homology and 3-D similarity no potent MDMX antagonist has been disclosed up to date. The current review summarizes the different disclosed chemotypes for MDM2 including a discussion of the cocrystal structures. Structures and approaches to reconstitute functional p53 from mutated p53 are presented. Finally new screening methods and recent biotech deals based on p53 are discussed.

Entities:  

Year:  2011        PMID: 24466404      PMCID: PMC3898590          DOI: 10.1039/C0MD00248H

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  60 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3.

Authors:  Michele Dal Bo; Paola Secchiero; Massimo Degan; Daniela Marconi; Riccardo Bomben; Gabriele Pozzato; Gianluca Gaidano; Giovanni Del Poeta; Francesco Forconi; Giorgio Zauli; Valter Gattei
Journal:  Br J Haematol       Date:  2010-04-28       Impact factor: 6.998

3.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.

Authors:  Holly K Koblish; Shuyuan Zhao; Carol F Franks; Robert R Donatelli; Rose M Tominovich; Louis V LaFrance; Kristi A Leonard; Joan M Gushue; Daniel J Parks; Raul R Calvo; Karen L Milkiewicz; Juan José Marugán; Pierre Raboisson; Maxwell D Cummings; Bruce L Grasberger; Dana L Johnson; Tianbao Lu; Christopher J Molloy; Anna C Maroney
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

4.  Diastereoselective synthesis of gamma-lactams by a one-pot, four-component reaction.

Authors:  Jingqiang Wei; Jared T Shaw
Journal:  Org Lett       Date:  2007-08-31       Impact factor: 6.005

5.  Synthesis of diverse lactam carboxamides leading to the discovery of a new transcription-factor inhibitor.

Authors:  Pui Yee Ng; Yuchen Tang; Wendy M Knosp; H Scott Stadler; Jared T Shaw
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

6.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.

Authors:  Grzegorz M Popowicz; Anna Czarna; Tad A Holak
Journal:  Cell Cycle       Date:  2008-05-27       Impact factor: 4.534

Review 7.  Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).

Authors:  Lutz Weber
Journal:  Expert Opin Ther Pat       Date:  2010-02       Impact factor: 6.674

Review 8.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Authors:  Grzegorz M Popowicz; Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-21       Impact factor: 15.336

9.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

Review 10.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

View more
  13 in total

1.  Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Authors:  Yijun Huang; Siglinde Wolf; David Koes; Grzegorz M Popowicz; Carlos J Camacho; Tad A Holak; Alexander Dömling
Journal:  ChemMedChem       Date:  2011-09-27       Impact factor: 3.466

2.  Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.

Authors:  Bing Shan; Da-Wei Li; Lei Brüschweiler-Li; Rafael Brüschweiler
Journal:  J Biol Chem       Date:  2012-07-17       Impact factor: 5.157

3.  Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists.

Authors:  S Shaabani; C G Neochoritis; A Twarda-Clapa; B Musielak; T A Holak; A Dömling
Journal:  Medchemcomm       Date:  2017-03-15       Impact factor: 3.597

4.  Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.

Authors:  Wei Wang; Haiping Cao; Siglinde Wolf; Miguel S Camacho-Horvitz; Tad A Holak; Alexander Dömling
Journal:  Bioorg Med Chem       Date:  2012-06-20       Impact factor: 3.641

Review 5.  P53 mdm2 inhibitors.

Authors:  Kareem Khoury; Alex Dömling
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Understanding the interaction of 14-3-3 proteins with hDMX and hDM2: a structural and biophysical study.

Authors:  Sonja Srdanović; Madita Wolter; Chi H Trinh; Christian Ottmann; Stuart L Warriner; Andrew J Wilson
Journal:  FEBS J       Date:  2022-03-28       Impact factor: 5.622

Review 7.  Targeting p53-MDM2-MDMX loop for cancer therapy.

Authors:  Qi Zhang; Shelya X Zeng; Hua Lu
Journal:  Subcell Biochem       Date:  2014

Review 8.  How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.

Authors:  Natalia Estrada-Ortiz; Constantinos G Neochoritis; Alexander Dömling
Journal:  ChemMedChem       Date:  2015-12-16       Impact factor: 3.466

9.  Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.

Authors:  Valeria Azzarito; Philip Rowell; Anna Barnard; Thomas A Edwards; Andrew Macdonald; Stuart L Warriner; Andrew J Wilson
Journal:  Chembiochem       Date:  2016-01-21       Impact factor: 3.164

Review 10.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.

Authors:  Yujun Zhao; Angelo Aguilar; Denzil Bernard; Shaomeng Wang
Journal:  J Med Chem       Date:  2014-11-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.